Skip to content

Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

A Retrospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04873180
Enrollment
40
Registered
2021-05-05
Start date
2020-01-01
Completion date
2020-12-30
Last updated
2021-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Renal Cell Carcinoma, Survivin, Immnuohistochemistry

Brief summary

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Detailed description

renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Interventions

DIAGNOSTIC_TESTsectioning and staining of renal neoplasms after nephrectomy operation

nephrectomy operations will be done to patients diagnosed as having renel tumors

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients suffer from renal cell carcinomas

Exclusion criteria

* patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Design outcomes

Primary

MeasureTime frameDescription
expression of survivin in neoplastic and adjacent normal renal tissuesapril, 2021Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026